Joint BIA and Harwell Campus Networking Lunch

Barbara Ghinelli

Harwell Campus Business Development Director, STFC

Barbara oversees the development and management of clusters on the Harwell and Daresbury Campuses. She has established a high profile for the Space and the HealthTec Clusters and is leading the development of new Clusters including EnergyTec. Barbara joined STFC in 2010 as Executive Director of Business Development. Successes included the creation of ISIC (now Satellite Application Catapult) at Harwell and of the High Performance Computing Centre (Hartree) at Daresbury. Barbara joined STFC from EADS Astrium (now Airbus DS), where she managed Business Development across Europe for the €3.2 billion joint ESA / EU Earth Observation Programme for Global Monitoring of Environment and Security (now Copernicus) and secured a number of large contracts. She graduated in Electronic Engineering at the University of York, completed her PhD in Artificial Intelligence and Radar Imaging at the University of Sheffield and holds a Certificate in Management from the Open University

Steve Bates OBE

Chief Executive Officer

What does your role at BIA involve?

Steve Bates is the CEO of the UK Bioindustry Association, the UK’s Trade Association for innovative life science companies with over 550 members. Steve is the visible face of the vibrant UK life sciences industry to government and media. He serves on the UK Government’s Life Sciences Council and the UK Biosecurity Leadership Council. Steve was a founder member of the UK Government’s Vaccine Taskforce in the Covid crisis, sitting on its steering Board alongside Kate Bingham. He is active member and former chair the International Council of Biotech Associations and has been a board member of EuropaBio since 2015.

Previous experience & achievements

Steve has championed, with government, effective industrial incentives like the Biomedical Catalyst, which have crowded in private sector investment into UK SMEs. He is a driving force behind the scale up agenda, spearheading policy agenda to unlock UK pension fund capital into productive UK growth in life sciences. He has forged several links for the sector across the USA, Europe and in China. In his time at the BIA, Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before joining the BIA in 2012, Steve worked for Genzyme and was advisor to the UK Government of Tony Blair working on NHS reform and the Northern Ireland peace process. He was made OBE for services to innovation in 2017 and became a Fellow of the Academy of Medical Science in 2020.

Dr Hadrian Green

CEO and Director, OxSyBio

Dr Green joined OxSyBio with more than a decade of experience working with global pharmaceutical and diagnostics companies as well as biotech companies and governments to drive the translation of science into next generation life-science businesses. This experience with Marakon Associates, Merck, GSK and Ernst & Young spans corporate and business unit strategy & transactions with a particular focus on personalised healthcare, clinical diagnostics, and small molecule and biological drug development. Hadrian graduated in Medicine and practiced across Australasia, the UK and several developing countries before earning a PhD in Molecular Imaging at the University of Cambridge in Molecular Imaging. Hadrian is a Fellow of the Cambridge Commonwealth Trust and was previously a bye-fellow of Queens’ College Cambridge.

Andy Hill

Director of Business Development, Oxford Academic Science Network

Andy is a life-sciences graduate and MBA with over 30 years’ experience in the medical technology industry as an executive and entrepreneur. His background is in sales, marketing and general management and he has a track record in the introduction of new and disruptive medical technologies into Europe and the USA. Andy has a particular interest in the creation and scaling of new technology businesses. Andy built the European businesses (from first in human use to exit) for two US start-ups and has led businesses as a CEO in a diverse range of medical technology sectors, including interventional vascular, patient monitoring, imaging and AI. He cofounded and was a lead investor in an Oxford University spinout. More recently, following a period consulting, Andy took responsibility for business development at the Oxford Academic Health Science Network (AHSN).

Nick Appleyard

Head of Downstream Business Applications, European Space Agency

Rhodri Davies

Senior Director of Production, Oxford Nanopore Technologies

Nick Scott-Ram

Chief of Data Analytics, Partnerships & Delivery and Commercial Director, Sensyne Health plc

Nick Scott-Ram is the Chief of Data Analytics, Partnerships & Delivery and Commercial Director, SENSIGHT – Life Sciences at Sensyne Health and is also a Director at the Oxford Martin School, University of Oxford. He has over 25 years of experience in commercial and business development in the life sciences sector, particularly in pharmaceuticals and also has an MA in Natural Sciences and a PhD in the Philosophy of Science from Cambridge University. He has worked in blue chip life science companies such as Oxford BioMedica and PowderJect Pharmaceuticals where he was VP Corporate Affairs, responsible for strategy. Previously, he was the Director of Commercial Development at the Oxford AHSN where he was responsible for the development of strategic partnerships with major pharmaceutical companies. Nick has extensive experience in commercial strategy, business development and pharmaceutical pricing. He led the life sciences industry position on the Biotechnology Patents Directive through the European Parliament in the 1990s. In 2001 Nick was awarded the MBE for services to biotechnology in 2001.